Menopausal hormone therapy and primary liver cancer: long-term follow-up of the women’s health initiative randomized trials
Open Access
- 16 September 2026
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- p. 1-7
Abstract
Background: Long-term results on liver cancer incidence and mortality are reported from two Women’s Health Initiative randomized trials evaluating menopausal hormone therapy. Methods: 16,608 postmenopausal women with a uterus were randomized to conjugated equine estrogen (CEE) 0.625 mg/d plus medroxyprogesterone acetate (MPA) 2.5 mg/d or placebo and 10,739 women with hysterectomy were randomized to 0.625 mg/d of CEE-alone or placebo. Results: After nearly 24 years follow-up and 74 incident liver cancers, neither CEE-alone nor CEE plus MPA influenced liver cancer development (CEE-alone vs placebo (11 vs 15 cancers; hazard ratio [HR] 0.75; 95% CI, 0.34-1.63; CEE plus MPA vs placebo (30 vs 18 cancers; HR 1.63; 95% CI, 0.91-2.92). CEE plus MPA did not significantly influence liver cancer mortality: 27 vs 22 deaths (HR 1.18; 95% CI, 0.67-2.07). In subgroup analyses, CEE plus MPA vs placebo was associated with more liver cancers among women aged 50-59 years (10 vs 0 cancers (P-trend 0.01) and prior oral contraceptive users (HR 4.30, 95% CI, 1.46-12.72; P-interaction 0.01). Conclusions: These findings indicate no overall influence of menopausal hormone therapy on liver cancer incidence or mortality although a possible increased risk with CEE plus MPA in select subgroups warrants further investigation. Trial Registration: clinicaltrials.gov Identifier: NCT00000611Keywords
Funding Information
- National Cancer Institute (LRP0000062905)
This publication has 31 references indexed in Scilit:
- Oral contraceptive use and risk of liver cancer: a population-based study, systematic review, and meta-analysisThe Lancet Oncology, 2025
- The Women’s Health Initiative Randomized Trials and Clinical PracticeJAMA, 2024
- Randomized trials of estrogen-alone and breast cancer incidence: a meta-analysisBreast Cancer Research and Treatment, 2024
- Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical TrialsJAMA, 2020
- Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific MortalityJAMA, 2017
- Population attributable fractions of risk factors for hepatocellular carcinoma in the United StatesCancer, 2016
- Menopausal hormone therapy use and risk of primary liver cancer in the clinical practice research datalinkInternational Journal of Cancer, 2015
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Design of the Women’s Health Initiative Clinical Trial and Observational StudyControlled Clinical Trials, 1998